188 related articles for article (PubMed ID: 34995471)
1. Genotype-Guided Antiplatelet Therapy Versus Standard Therapy for Patients with Coronary Artery Disease: An Updated Systematic Review and Meta-Analysis.
Tang B; Wang X; Wang X; Liu L; Ma Z
J Pharm Pharm Sci; 2022; 25():9-23. PubMed ID: 34995471
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
Lyu SQ; Yang YM; Zhu J; Wang J; Wu S; Zhang H; Shao XH; Ren JM
Platelets; 2020 Nov; 31(8):971-980. PubMed ID: 32546030
[TBL] [Abstract][Full Text] [Related]
3. CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials.
Kheiri B; Osman M; Abdalla A; Haykal T; Pandrangi PV; Chahine A; Ahmed S; Osman K; Bachuwa G; Hassan M; Bhatt DL
Catheter Cardiovasc Interv; 2019 Jun; 93(7):1246-1252. PubMed ID: 30403317
[TBL] [Abstract][Full Text] [Related]
4. Genotype-guided antiplatelet therapy compared with standard therapy for patients with acute coronary syndromes or undergoing percutaneous coronary intervention: A systematic review and meta-analysis.
Wang X; Wang S; Yang J; Yu X; Liu L
Thromb Res; 2020 Sep; 193():130-138. PubMed ID: 32559569
[TBL] [Abstract][Full Text] [Related]
5. Genotype-guided antiplatelet therapy compared with conventional therapy for patients with acute coronary syndromes: a systematic review and meta-analysis.
Zheng L; Yang C; Xiang L; Hao Z
Biomarkers; 2019 Sep; 24(6):517-523. PubMed ID: 31215825
[TBL] [Abstract][Full Text] [Related]
6. Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Galli M; Benenati S; Capodanno D; Franchi F; Rollini F; D'Amario D; Porto I; Angiolillo DJ
Lancet; 2021 Apr; 397(10283):1470-1483. PubMed ID: 33865495
[TBL] [Abstract][Full Text] [Related]
7. Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis.
Zhang L; Yang J; Zhu X; Wang X; Peng L; Li X; Cheng P; Yin T
Thromb Res; 2015 Mar; 135(3):449-58. PubMed ID: 25511576
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of genotype-guided antiplatelet therapy versus standard treatment in 4,604 patients with CAD after PCI: a meta-analysis of randomized controlled trials.
Liu D; Zhao Li Y; Wu H; Zhou G; Yang J; Yang J; Ding JW; Fan ZX; Yang CJ
Pharmazie; 2020 Dec; 75(12):651-655. PubMed ID: 33303059
[No Abstract] [Full Text] [Related]
9. Personalized antiplatelet therapy in patients with coronary artery disease undergoing percutaneous coronary intervention: A network meta-analysis of randomized clinical trials.
Kheiri B; Abdalla A; Osman M; Barbarawi M; Zayed Y; Haykal T; Chahine A; Bachuwa G; Hassan M; Bhatt DL
Catheter Cardiovasc Interv; 2019 Aug; 94(2):181-186. PubMed ID: 30628754
[TBL] [Abstract][Full Text] [Related]
10. Risk of major adverse cardiovascular events of
Biswas M; Kali MSK; Biswas TK; Ibrahim B
Platelets; 2021 Jul; 32(5):591-600. PubMed ID: 32664772
[TBL] [Abstract][Full Text] [Related]
11. Genotype-guided personalization of antiplatelet treatment: A meta-analysis of patients with ACS or undergoing PCI.
Liu J; Qin L; Xi S; Tong W; Yuan M; Peng L; Liu J; Wang X; Zhang Y; Yin T
Thromb Res; 2019 Jul; 179():87-94. PubMed ID: 31100633
[TBL] [Abstract][Full Text] [Related]
12. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
Pereira NL; Farkouh ME; So D; Lennon R; Geller N; Mathew V; Bell M; Bae JH; Jeong MH; Chavez I; Gordon P; Abbott JD; Cagin C; Baudhuin L; Fu YP; Goodman SG; Hasan A; Iturriaga E; Lerman A; Sidhu M; Tanguay JF; Wang L; Weinshilboum R; Welsh R; Rosenberg Y; Bailey K; Rihal C
JAMA; 2020 Aug; 324(8):761-771. PubMed ID: 32840598
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of short-term (1 to 3 months) dual antiplatelet therapy in patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials.
Kheiri B; Simpson TF; Osman M; Golwala H; Radaideh Q; Kumar K; Rahmouni H; Divanji P; Cigarroa JE; Zahr F
J Thromb Thrombolysis; 2020 Nov; 50(4):867-873. PubMed ID: 32607653
[TBL] [Abstract][Full Text] [Related]
14. The optimal discontinuation of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention with drug-eluting stents: A meta-analysis of randomized trials.
Wang W; Liu J; Fang J; Liu Y; An T; Zou M; Cheng G
Int J Cardiol; 2017 May; 235():73-86. PubMed ID: 28284499
[TBL] [Abstract][Full Text] [Related]
15. Effects of Cilostazol-Based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy After Coronary Drug-Eluting Stent Implantation: An Updated Meta-Analysis of the Randomized Controlled Trials.
Zhao S; Zhong Z; Qi G; Shi L; Tian W
Clin Drug Investig; 2019 Jan; 39(1):1-13. PubMed ID: 30251232
[TBL] [Abstract][Full Text] [Related]
16. Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials.
Bundhun PK; Qin T; Chen MH
BMC Cardiovasc Disord; 2015 Oct; 15():118. PubMed ID: 26450578
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of triple-antiplatelet therapy after percutaneous coronary intervention: a meta-analysis.
Zhang Y; Tang HQ; Li J; Fu ZX
Chin Med J (Engl); 2013; 126(9):1750-4. PubMed ID: 23652062
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of single vs dual antiplatelet therapy in patients on anticoagulation undergoing percutaneous coronary intervention: A systematic review and meta-analysis.
Atti V; Turagam MK; Garg J; Velagapudi P; Patel NJ; Basir MB; Mujer MT; Rayamajhi S; Abela GS; Koerber S; Gopinnathanair R; Lakkireddy D
J Cardiovasc Electrophysiol; 2019 Nov; 30(11):2460-2472. PubMed ID: 31432607
[TBL] [Abstract][Full Text] [Related]
19. Genotype-guided antiplatelet treatment versus conventional therapy: A systematic review and meta-analysis.
Zhang H; Xiang Q; Liu Z; Mu G; Xie Q; Zhou S; Ma L; Wang Z; Hu K; Wang Z; Cui Y
Br J Clin Pharmacol; 2021 May; 87(5):2199-2215. PubMed ID: 33140858
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of short-term 1-3 months versus standard 12 months dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials.
Zhang WJ; Qiao X; Liang XY; Li Y; Yang RR; Wang ZL
Platelets; 2021 Jul; 32(5):582-590. PubMed ID: 32627616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
